{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:01:36Z","timestamp":1772463696218,"version":"3.50.1"},"reference-count":234,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100008530","name":"FEDER funds through the POCI - COMPETE 2020","doi-asserted-by":"publisher","award":["7491"],"award-info":[{"award-number":["7491"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"National Funds by FCT - Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/Multi\/00709"],"award-info":[{"award-number":["UID\/Multi\/00709"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2018,12,13]]},"abstract":"<jats:sec><jats:title\/><jats:p>Hepatocellular carcinoma (HCC) is the most frequently detected primary malignant liver tumor, representing a worldwide public health problem due to its high morbidity and mortality rates. The HCC is commonly detected in advanced stage, precluding the use of treatments with curative intent. For this reason, it is crucial to find effective therapies for HCC. Cancer cells have a high dependence of glycolysis for ATP production, especially under hypoxic environment. Such dependence provides a reliable possible strategy to specifically target cancer cells based on the inhibition of glycolysis. HCC, such as other cancer types, presents a clinically well-known upregulation of several glycolytic key enzymes and proteins, including glucose transporters particularly glucose transporter 1 (GLUT1). Such enzymes and proteins constitute potential targets for therapy. Indeed, for some of these targets, several inhibitors were already reported, such as 2-Deoxyglucose, Imatinib or Flavonoids. Although the inhibition of glycolysis presents a great potential for an anticancer therapy, the development of glycolytic inhibitors as a new class of anticancer agents needs to be more explored. Herein, we propose to summarize, discuss and present an overview on the different approaches to inhibit the glycolytic metabolism in cancer cells, which may be very effective in the treatment of HCC.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568009618666180430144441","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T11:36:47Z","timestamp":1525174607000},"page":"26-40","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?"],"prefix":"10.2174","volume":"19","author":[{"given":"A.P.","family":"Alves","sequence":"first","affiliation":[{"name":"Centro de Investigacao em Ciencias da Saude (CICS-UBI), Universidade da Beira Interior, Covilha, Portugal"}]},{"given":"A.C.","family":"Mamede","sequence":"additional","affiliation":[{"name":"Centro de Investigacao em Ciencias da Saude (CICS-UBI), Universidade da Beira Interior, Covilha, Portugal"}]},{"given":"M.G.","family":"Alves","sequence":"additional","affiliation":[{"name":"Centro de Investigacao em Ciencias da Saude (CICS-UBI), Universidade da Beira Interior, Covilha, Portugal"}]},{"given":"P.F.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar (ICBAS) and Unit for Multidisciplinary Research in Biomedicine (UMIB), University of Porto, Porto, Portugal"}]},{"given":"S.M.","family":"Rocha","sequence":"additional","affiliation":[{"name":"Centro de Investigacao em Ciencias da Saude (CICS-UBI), Universidade da Beira Interior, Covilha, Portugal"}]},{"given":"M.F.","family":"Botelho","sequence":"additional","affiliation":[{"name":"Biophysics Unit, Faculty of Medicine, University of Coimbra, Coimbra, Portugal"}]},{"given":"C.J.","family":"Maia","sequence":"additional","affiliation":[{"name":"Centro de Investigacao em Ciencias da Saude (CICS-UBI), Universidade da Beira Interior, Covilha, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","volume":"48","author":"Llovet J.M.","year":"2008","unstructured":"Llovet JM, Bruix J. Hepatology, Molecular targeted therapies in hepatocellular carcinoma.,, 2008, 48,, 1312-1327,","journal-title":"Hepatology"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/gast.2001.27126","volume":"121","author":"Reid A.E.","year":"2001","unstructured":"Reid AE. Gastroenterology, Nonalcoholic steatohepatitis.,, 2001, 121,, 710-723,","journal-title":"Gastroenterology"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/gast.2002.33411","volume":"122","author":"Befeler A.S.","year":"2002","unstructured":"Befeler AS, Di Bisceglie AM. Gastroenterology, Hepatocellular carcinoma: diagnosis and treatment.,, 2002, 122,, 1609-1619,","journal-title":"Gastroenterology"},{"key":"ref=4","first-page":"1","volume":"49","author":"Jemal A.","year":"1999","unstructured":"Jemal A, Bray F, Ferlay J. CA Cancer J Clin, Global cancer statistics: 2011.,, 1999, 49,, 1-, 33-64,","journal-title":"CA Cancer J Clin"},{"key":"ref=5","author":"Ant\u00f3nio M.","year":"2013","unstructured":"Ant\u00f3nio M, Gon\u00e7alves D. Hepatocellular carcinoma\u202f: epidemiology, biology, diagnosis, and therapies q., , , 2013","journal-title":"Hepatocellular carcinoma\u202f: epidemiology, biology, diagnosis, and therapies q"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"Torre L.A.","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Cancer J Clin, Global cancer statistics, 2012.,, 2015, 65,, 87-108,","journal-title":"Cancer J Clin"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","volume":"7","author":"Yang J.","year":"2010","unstructured":"Yang J, Roberts L. Nat Rev Gastroenterol Hepatol, Hepatocellular carcinoma: a global view.,, 2010, 7,, 448-458,","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"Llovet J.M.","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. J Natl Cancer Inst, Design and endpoints of clinical trials in hepatocellular carcinoma.,, 2008, 100,, 698-711,","journal-title":"J Natl Cancer Inst"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"El-Serag H.B.","year":"2012","unstructured":"El-Serag HB. Gastroenterol, Epidemiology of viral hepatitis and hepatocellular carcinoma.,, 2012, 142,, 1264-1273,","journal-title":"Gastroenterol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1053\/jhep.2002.33165","volume":"35","author":"Lee J-S.","year":"2002","unstructured":"Lee J-S, Thorgeirsson SS. Hepatology, Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer.,, 2002, 35,, 1134-1143,","journal-title":"Hepatology"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1665-2681(19)31582-0","volume":"10","author":"Alves R.","year":"2011","unstructured":"Alves R, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P. Ann Hepatol, Advanced hepatocellular carcinoma: review of targeted molecular drugs.,, 2011, 10,, 21-27,","journal-title":"Ann Hepatol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"El-Serag H.B.","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Gastroenterology, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.,, 2007, 132,, 2557-2576,","journal-title":"Gastroenterology"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2007.06.025","volume":"133","author":"Mayhew C.N.","year":"2007","unstructured":"Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, Aronow BJ. Gastroenterology, RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis.,, 2007, 133,, 976-984,","journal-title":"Gastroenterology"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/ijo.2012.1474","volume":"41","author":"Popescu N.","year":"2012","unstructured":"Popescu N, Popescu NC. Int J Oncol, Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: Potential prospects for combined targeted therapeutics.,, 2012, 41,, 393-406,","journal-title":"Int J Oncol"},{"key":"ref=15","first-page":"1504","volume":"52","author":"Tsuda H.","year":"1992","unstructured":"Tsuda H, Oda T, Sakamoto M, Hirohashi S. Cancer Res, Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin.,, 1992, 52,, 1504-1509,","journal-title":"Cancer Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/dna.2010.1126","volume":"30","author":"Ding J.","year":"2011","unstructured":"Ding J, Gao Y, Liu R, Xu F, Liu H. DNA Cell Biol, Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a han chinese population.,, 2011, 30,, 229-234,","journal-title":"DNA Cell Biol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1159\/000430292","volume":"36","author":"Tang W.","year":"2015","unstructured":"Tang W, Feng X, Zhang S, Ren Z, Liu Y, Yang B. Cell Physiol Biochem, lv, B.; Cai, Y.; Xia, J.; Ge, N. Caveolin-1 confers resistance of hepatoma cells to anoikis by activating IGF-1 pathway.,, 2015, 36,, 1223-1236,","journal-title":"Cell Physiol Biochem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.27887","volume":"62","author":"Zhou J.N.","year":"2015","unstructured":"Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, Jia YL, Wang JX, Zhao AH, Li ZW, Li YH, Xie XY, Zhang XM, Dong Y, Xu YC, He LJ, Yue W, Pei XT. Hepatology, MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.,, 2015, 62,, 801-815,","journal-title":"Hepatology"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s10620-014-3058-x","volume":"59","author":"Galuppo R.","year":"2014","unstructured":"Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Dig Dis Sci, Molecular therapies in hepatocellular carcinoma: what can we target?,, 2014, 59,, 1688-1697,","journal-title":"Dig Dis Sci"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2217\/fon.11.95","volume":"7","author":"Zhou Q.","year":"2011","unstructured":"Zhou Q, Yeo W. Future Oncol, Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma.,, 2011, 7,, 1149-1167,","journal-title":"Future Oncol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.21651","volume":"45","author":"Thompson M.D.","year":"2007","unstructured":"Thompson MD, Monga SPS. Hepatology, WNT\/\u03b2-catenin signaling in liver health and disease.,, 2007, 45,, 1298-1305,","journal-title":"Hepatology"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature01972","volume":"425","author":"Berman D.M.","year":"2003","unstructured":"Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. Nature, Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.,, 2003, 425,, 846-851,","journal-title":"Nature"},{"key":"ref=23","first-page":"1","volume":"4","author":"Strazzabosco M.","year":"2012","unstructured":"Strazzabosco M, Fabris L. Gastroenterology, Notch signaling in hepatocellular carcinoma: guilty in association.,, 2012, 4,, 1-4,","journal-title":"Gastroenterology"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2012.09.002","volume":"143","author":"Villanueva A.","year":"2012","unstructured":"Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Sol\u00e9 M, Thung S, Stanger BZ, Llovet JM. Gastroenterology, Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.,, 2012, 143,, 1660-1669,","journal-title":"Gastroenterology"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4254\/wjh.v6.i10.716","volume":"6","author":"Enguita-Germ\u00e1n M.","year":"2014","unstructured":"Enguita-Germ\u00e1n M, Fortes P. W J Hepatol, Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.,, 2014, 6,, 716-737,","journal-title":"W J Hepatol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00535-013-0907-x","volume":"49","author":"Berasain C.","year":"2014","unstructured":"Berasain C, Avila MA. J Gastroenterol, The EGFR signalling system in the liver: From hepatoprotection to hepatocarcinogenesis.,, 2014, 49,, 9-23,","journal-title":"J Gastroenterol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.24653","volume":"55","author":"Morris S.M.","year":"2012","unstructured":"Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Hepatology, Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.,, 2012, 55,, 121-131,","journal-title":"Hepatology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"Bruix J.","year":"2005","unstructured":"Bruix J, Sherman M. Hepatology, Management of hepatocellular carcinoma.,, 2005, 42,, 1208-1236,","journal-title":"Hepatology"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"Llovet J.M.","year":"2003","unstructured":"Llovet JM, Bruix J. Hepatology, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.,, 2003, 37,, 429-442,","journal-title":"Hepatology"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/1098-2388(200009)19:2<116::AID-SSU4>3.0.CO;2-F","volume":"19","author":"Johnson P.","year":"2000","unstructured":"Johnson P. Semin Surg Oncol, Systemic chemotherapy of liver tumors.,, 2000, 19,, 116-124,","journal-title":"Semin Surg Oncol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"\u2022\u2022\u2022","author":"Llovet J.M.","year":"2003","unstructured":"Llovet JM, Burroughs ABJ. Lancet, Hepatocellular carcinoma.,, 2003, \u2022\u2022\u2022,, 1907-1917,","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.18632\/oncotarget.466","volume":"3","author":"Cervello M.","year":"2012","unstructured":"Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Oncotarget, Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.,, 2012, 3,, 236-260,","journal-title":"Oncotarget"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"Liu L.","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Cancer Res, Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5.,, 2006, 66,, 11851-11858,","journal-title":"Cancer Res"},{"key":"ref=34","first-page":"779","volume":"2","author":"Furuse J.","year":"2008","unstructured":"Furuse J. Biologics\u202f: Targets Ther, Sorafenib for the treatment of unresectable hepatocellular carcinoma.,, 2008, 2,, 779-788,","journal-title":"Biologics\u202f: Targets Ther"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2162-3619-2-8","volume":"2","author":"Wrzesinski S.H.","year":"2013","unstructured":"Wrzesinski SH, Fisher JL, Ernstoff MS. Exp Hematol Oncol, Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo.,, 2013, 2,, 8-,","journal-title":"Exp Hematol Oncol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Warburg O.","year":"1956","unstructured":"Warburg O. Science, On the origin of cancer cells.,, 1956, 123,, 309-314,","journal-title":"Science"},{"key":"ref=37","author":"Warburg O.","unstructured":"Warburg O, Posener K, Negolein E, , Biochem. Zeitschr,, , , Ueber den stoffwechsel der tumoren (The metabolism of tumor cells)., 1924,129-169","journal-title":"Ueber den stoffwechsel der tumoren (The metabolism of tumor cells)"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"Gatenby R.A.","year":"2004","unstructured":"Gatenby RA, Gillies RJ. Nat Rev Cancer, Why do cancers have high aerobic glycolysis?,, 2004, 4,, 891-899,","journal-title":"Nat Rev Cancer"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/14728220903307509","volume":"13","author":"Amann T.","year":"2009","unstructured":"Amann T, Hellerbrand C. Expert Opin Ther Targets, GLUT1 as a therapeutic target in hepatocellular carcinoma.,, 2009, 13,, 1411-1427,","journal-title":"Expert Opin Ther Targets"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","volume":"174","author":"Amann T.","year":"2009","unstructured":"Amann T. Am J Pathol, Maegdefrau, U.; Hartmann, A.; Agaimy, A.; Marienhagen, J.; Weiss, T.S.; Stoeltzing, O.; Warnecke, C.; Sch\u00f6lmerich, J.; Oefner, P.J.; Kreutz, M.; Bosserhoff, A.K.; Hellerbrand, C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.,, 2009, 174,, 1544-1552,","journal-title":"Am J Pathol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-1-9","volume":"1","author":"Carew J.S.","year":"2002","unstructured":"Carew JS, Huang P. Mol Cancer, Mitochondrial defects in cancer.,, 2002, 1,, 9-,","journal-title":"Mol Cancer"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1383-5742(01)00053-9","volume":"488","author":"Penta J.S.","year":"2001","unstructured":"Penta JS, Johnson FM, Wachsman JT, Copeland WC. Rev Mutation Res, Mitochondrial DNA in human malignancy.,, 2001, 488,, 119-133,","journal-title":"Rev Mutation Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12307-008-0006-3","volume":"1","author":"Dayan F.","year":"2008","unstructured":"Dayan F, Mazure NM, Brahimi-Horn MC, Pouyss\u00e9gur JA. Cancer Microenviron, Dialogue between the hypoxia-inducible factor and the tumor microenvironment.,, 2008, 1,, 53-68,","journal-title":"Cancer Microenviron"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"Brahimi-Horn M.C.","year":"2007","unstructured":"Brahimi-Horn MC, Chiche J, Pouyss\u00e9gur J. J Mol Med (Berl), Hypoxia and cancer.,, 2007, 85,, 1301-1307,","journal-title":"J Mol Med (Berl)"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/157489212799972891","volume":"7","author":"Pandey P.R.","year":"2012","unstructured":"Pandey PR, Liu W, Xing F, Fukuda K, Watabe K. Recent Patents Anticancer Drug Discov, Anti-cancer drugs targeting fatty acid synthase (FAS).,, 2012, 7,, 185-197,","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1196\/annals.1297.043","volume":"1019","author":"Singh K.K.","year":"2004","unstructured":"Singh KK. Ann N Y Acad Sci, Mitochondrial dysfunction is a common phenotype in aging and cancer.,, 2004, 1019,, 260-264,","journal-title":"Ann N Y Acad Sci"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.3103217","volume":"235","author":"Flier J.","year":"1987","unstructured":"Flier J, Mueckler M, Usher P, Lodish H. Science, Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes.,, 1987, 235,, 1492-1495,","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","volume":"64","author":"Elstrom R.L.","year":"2004","unstructured":"Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris M, Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Cancer Res, Akt stimulates aerobic glycolysis in cancer cells.,, 2004, 64,, 3892-3899,","journal-title":"Cancer Res"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1016\/S0021-9258(19)68900-3","volume":"256","author":"Bustamante E.","year":"1981","unstructured":"Bustamante E, Morris HP, Pedersen PL. J Biol Chem, Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding.,, 1981, 256,, 8699-8704,","journal-title":"J Biol Chem"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"Selak M.A.","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Cancer Cell, Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-? prolyl hydroxylase.,, 2005, 7,, 77-85,","journal-title":"Cancer Cell"},{"key":"ref=51","first-page":"5745","volume":"56","author":"Gatenby R.A.","year":"1996","unstructured":"Gatenby RA, Gawlinski ET. Cancer Res, A reaction-diffusion model of cancer invasion.,, 1996, 56,, 5745-5753,","journal-title":"Cancer Res"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0027-5107(92)90235-T","volume":"268","author":"Morita T.","year":"1992","unstructured":"Morita T, Nagaki T, Fukuda I, Okumura K. Mutat Res, Clastogenicity of low pH to various cultured mammalian cells.,, 1992, 268,, 297-305,","journal-title":"Mutat Res"},{"key":"ref=53","author":"Raghunand N.","year":"2003","unstructured":"Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours., , , 2003","journal-title":"Microenvironmental and cellular consequences of altered blood flow in tumours"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/carcin\/11.6.909","volume":"11","author":"Ruch R.J.","year":"1990","unstructured":"Ruch RJ, Klaunig JE, Klaunig JE, Kerckaert GA, LeBoeuf RA, LeBoeuf RA. Carcinogenesis, Modification of gap junctional intercellular communication by changes in extracellular pH in Syrian hamster embryo cells.,, 1990, 11,, 909-913,","journal-title":"Carcinogenesis"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","volume":"8","author":"Semenza G.L.","year":"1998","unstructured":"Semenza GL. Curr Opin Genet Dev, Hypoxia-inducible factor 1: Master regulator of O2 homeostasis.,, 1998, 8,, 588-594,","journal-title":"Curr Opin Genet Dev"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0168-8278(03)00503-8","volume":"40","author":"Yasuda S.","year":"2004","unstructured":"Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Imamura M. J Hepatol, Hexokinase II and VEGF expression in liver tumors: Correlation with hypoxia-inducible factor-1\u03b1 and its significance.,, 2004, 40,, 117-123,","journal-title":"J Hepatol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","volume":"394","author":"Carmeliet P.","year":"1998","unstructured":"Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Nature, Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.,, 1998, 394,, 485-490,","journal-title":"Nature"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biopha.2014.12.010","volume":"69","author":"Dong T.","year":"2015","unstructured":"Dong T, Yan Y, Chai H, Chen S, Xiong X, Sun D, Yu Y, Deng L, Cheng F. Biomed Pharmacother, Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1\u03b1 and Bcl-xL in culture.,, 2015, 69,, 277-284,","journal-title":"Biomed Pharmacother"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/carcin\/bgs249","volume":"33","author":"Xia L.","year":"2012","unstructured":"Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y, Wu K. Carcinogenesis, The TNF-\u03b1\/ROS\/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.,, 2012, 33,, 2250-2259,","journal-title":"Carcinogenesis"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1021\/bi002426w","volume":"40","author":"Liu H.","year":"2001","unstructured":"Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Biochemistry, Hypersensitization of tumor cells to glycolytic inhibitors.,, 2001, 40,, 5542-5547,","journal-title":"Biochemistry"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2011.04.025","volume":"42","author":"Lv L.","year":"2011","unstructured":"Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY. Mol Cell, Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.,, 2011, 42,, 719-730,","journal-title":"Mol Cell"},{"key":"ref=62","first-page":"1","volume":"2","author":"Hitosugi T.","year":"2010","unstructured":"Hitosugi T, Kang S, Vander Heiden MG, Chung T, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J. Growth (Lakeland), NIH Public Access.,, 2010, 2,, 1-16,","journal-title":"Growth (Lakeland)"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Zhao Y.","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M. Cell Death Dis, Targeting cellular metabolism to improve cancer therapeutics.,, 2013, 4,, e532-,","journal-title":"Cell Death Dis"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bbabio.2010.11.006","volume":"1807","author":"Mar\u00edn-Hern\u00e1ndez A.","year":"2011","unstructured":"Mar\u00edn-Hern\u00e1ndez A, Gallardo-P\u00e9rez JC, Rodr\u00edguez-Enr\u00edquez S, Encalada R, Moreno-S\u00e1nchez R, Saavedra E. Biochim Biophys Acta, Modeling cancer glycolysis.,, 2011, 1807,, 755-767,","journal-title":"Biochim Biophys Acta"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4161\/cam.26345","volume":"7","author":"Han T.","year":"2013","unstructured":"Han T, Kang D, Ji D, Wang X, Zhan W, Fu M, Xin HB, Wang JB. Cell Adhes Migr, How does cancer cell metabolism affect tumor migration and invasion?,, 2013, 7,, 395-403,","journal-title":"Cell Adhes Migr"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molmed.2011.01.014","volume":"17","author":"Perl A.","year":"2011","unstructured":"Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. Trends Mol Med, Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase.,, 2011, 17,, 395-403,","journal-title":"Trends Mol Med"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00018-015-2098-5","volume":"73","author":"Payen V.L.","year":"2016","unstructured":"Payen VL, Porporato PE, Baselet B, Sonveaux P. Cell Mol Life Sci, Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.,, 2016, 73,, 1333-1348,","journal-title":"Cell Mol Life Sci"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbabio.2004.05.007","volume":"1658","author":"Izyumov D.S.","year":"2004","unstructured":"Izyumov DS, Avetisyan AV, Pletjushkina OY, Sakharov DV, Wirtz KW, Chernyak BV, Skulachev VP. Biochim Biophys Acta, Wages of fear: transient threefold decrease in intracellular ATP level imposes apoptosis.,, 2004, 1658,, 141-147,","journal-title":"Biochim Biophys Acta"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbabio.2004.05.007","volume":"1658","author":"Izyumov D.S.","year":"2004","unstructured":"Izyumov DS, Avetisyan AV, Pletjushkina OY, Sakharov DV, Wirtz KW, Chernyak BV, Skulachev VP. Biochim Biophys Acta, Wages of fear: transient threefold decrease in intracellular ATP level imposes apoptosis.,, 2004, 1658,, 141-147,","journal-title":"Biochim Biophys Acta"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"12759","DOI":"10.1074\/jbc.M212392200","volume":"278","author":"Munoz-Pinedo C.","year":"2003","unstructured":"Munoz-Pinedo C, Ruiz-Ruiz C, De Almodovar CR, Palacios C, Lopez-Rivas A. J Biol Chem, Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing.,, 2003, 278,, 12759-12768,","journal-title":"J Biol Chem"},{"key":"ref=70","author":"Xu R.","year":"2005","unstructured":"Xu R, Pelicano H, Zhou Y. Inhibition of glycolysis in cancer cells\u202f: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia inhibition of glycolysis in cancer cells\u202f: a novel strategy to overcome drug resistance associated with Mi., , , 2005","journal-title":"Inhibition of glycolysis in cancer cells\u202f: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia inhibition of glycolysis in cancer cells\u202f: a novel strategy to overcome drug resistance associated with Mi"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"Wood I.S.","year":"2003","unstructured":"Wood IS, Trayhurn P. Br J Nutr, Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.,, 2003, 89,, 3-9,","journal-title":"Br J Nutr"},{"key":"ref=72","author":"Lantos P.L.","year":"1986","unstructured":"Lantos PL, Park DC, Hill D. , , , 1986"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/carcin\/21.3.497","volume":"21","author":"Yokota J.","year":"2000","unstructured":"Yokota J. Carcinogenesis, Tumor progression and metastasis.,, 2000, 21,, 497-503,","journal-title":"Carcinogenesis"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.3748\/wjg.v18.i46.6771","volume":"18","author":"Karim S.","year":"2012","unstructured":"Karim S, Adams DH, Lalor PF. World J Gastroenterol, Hepatic expression and cellular distribution of the glucose transporter family.,, 2012, 18,, 6771-6781,","journal-title":"World J Gastroenterol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1349-7006.1999.tb00702.x","volume":"90","author":"Kurata T.","year":"1999","unstructured":"Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Jpn J Cancer Res, Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases.,, 1999, 90,, 1238-1243,","journal-title":"Jpn J Cancer Res"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bmb.2003.494031030227","volume":"31","author":"Gorovits N.","year":"2003","unstructured":"Gorovits N, Charron MJ. Biochem Mol Biol Educ, What we know about facilitative glucose transporters.,, 2003, 31,, 163-172,","journal-title":"Biochem Mol Biol Educ"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1074\/jbc.M113.522037","volume":"289","author":"Freemerman A.J.","year":"2014","unstructured":"Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L. J Biol Chem, Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype.,, 2014, 289,, 7884-7896,","journal-title":"J Biol Chem"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2337\/diab.37.5.657","volume":"37","author":"Fukumoto H.","year":"1988","unstructured":"Fukumoto H, Seino S, Imura H, Seino Y, Bell GI. Diabetes, Characterization and expression of human HepG2\/erythrocyte glucose-transporter gene.,, 1988, 37,, 657-661,","journal-title":"Diabetes"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000104457","volume":"53","author":"Airley R.E.","year":"2007","unstructured":"Airley RE, Mobasheri A. Chemotherapy, Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics.,, 2007, 53,, 233-256,","journal-title":"Chemotherapy"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.11.023","volume":"388","author":"Zhang H.L.","year":"2017","unstructured":"Zhang HL, Wang MD, Zhou X. Cancer Lett, Qin CJ2, Fu GB2, Tang L3, Wu H2, Huang S2, Zhao LH2, Zeng M2, Liu J2, Cao D2, Guo LN2, Wang HY4, Yan HX5, Liu J6. Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.,, 2017, 388,, 1-11,","journal-title":"Cancer Lett"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"15245","DOI":"10.1016\/S0021-9258(19)37577-5","volume":"263","author":"Kayano T.","year":"1988","unstructured":"Kayano T, Fukumoto H, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI. J Biol Chem, Evidence for a family of human glucose transporter-like proteins. Sequence and gene localization of a protein expressed in fetal skeletal muscle and other tissues.,, 1988, 263,, 15245-15248,","journal-title":"J Biol Chem"},{"key":"ref=82","author":"Gould G.W.","year":"1993","unstructured":"Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression., , , 1993","journal-title":"The glucose transporter family: structure, function and tissue-specific expression"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1677\/JOE-08-0262","volume":"200","author":"Schmidt S.","year":"2009","unstructured":"Schmidt S, Hommel A, Gawlik V, Augustin R, Junicke N, Florian S, Richter M, Walther DJ, Montag D, Joost HG, Sch\u00fcrmann A. J Endocrinol, Essential role of glucose transporter GLUT3 for post-implantation embryonic development.,, 2009, 200,, 23-33,","journal-title":"J Endocrinol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/138920207780368187","volume":"8","author":"Zhao F-Q.","year":"2007","unstructured":"Zhao F-Q, Keating AF. Curr Genomics, Functional properties and genomics of glucose transporters.,, 2007, 8,, 113-128,","journal-title":"Curr Genomics"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"42978","DOI":"10.1074\/jbc.M508678200","volume":"280","author":"Manolescu A.","year":"2005","unstructured":"Manolescu A, Salas-Burgos AM, Fischbarg J, Cheeseman CI. J Biol Chem, Identification of a hydrophobic residue as a key determinant of fructose transport by the facilitative hexose transporter SLC2A7 (GLUT7).,, 2005, 280,, 42978-42983,","journal-title":"J Biol Chem"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1152\/ajpendo.00712.2009","volume":"298","author":"Thorens B.","year":"2010","unstructured":"Thorens B, Mueckler M. Am J Physiol Endocrinol Metab, Glucose transporters in the 21st Century.,, 2010, 298,, E141-E145,","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000014989","volume":"81","author":"White P.S.","year":"1998","unstructured":"White PS, Jensen SJ, Rajalingam V, Stairs D, Sulman EP, Maris JM, Biegel JA, Wooster R, Brodeur GM. Cytogenet Cell Genet, Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2.,, 1998, 81,, 60-64,","journal-title":"Cytogenet Cell Genet"},{"key":"ref=88","author":"Corpe C.P.","unstructured":"Corpe CP, Bovelander FJ, Munoz CM, Hoekstra JH, Simpson IA, Kwon O, Levine M, Burant CF, , ,, , , Cloning and functional characterization of the mouse fructose transporter, GLUT5, 2002,-","journal-title":"Cloning and functional characterization of the mouse fructose transporter, GLUT5"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature13306","volume":"510","author":"Deng D.","year":"2014","unstructured":"Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, Yan N. Nature, Crystal structure of the human glucose transporter GLUT1.,, 2014, 510,, 121-125,","journal-title":"Nature"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nature14909","volume":"526","author":"Nomura N.","year":"2015","unstructured":"Nomura N, Verdon G, Kang HJ, Shimamura T, Nomura Y, Sonoda Y, Hussien SA, Qureshi AA, Coincon M, Sato Y, Abe H, Nakada-Nakura Y, Hino T, Arakawa T, Kusano-Arai O, Iwanari H, Murata T, Kobayashi T, Hamakubo T, Kasahara M, Iwata S, Drew D. Nature, Structure and mechanism of the mammalian fructose transporter GLUT5.,, 2015, 526,, 397-401,","journal-title":"Nature"},{"key":"ref=91","first-page":"1284","volume":"8","author":"Helmlinger G.","year":"2002","unstructured":"Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Clin Cancer Res, Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism.,, 2002, 8,, 1284-1291,","journal-title":"Clin Cancer Res"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.1998.289","volume":"77","author":"Yamagata M.","year":"1998","unstructured":"Yamagata M, Hasuda K, Stamato T, Tannock IF. Br J Cancer, The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase.,, 1998, 77,, 1726-1731,","journal-title":"Br J Cancer"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"47965","DOI":"10.1074\/jbc.X200007200","volume":"277","author":"Horecker B.L.","year":"2002","unstructured":"Horecker BL. J Biol Chem, The pentose phosphate pathway.,, 2002, 277,, 47965-47971,","journal-title":"J Biol Chem"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1369-5266(03)00039-6","volume":"6","author":"Kruger N.J.","year":"2003","unstructured":"Kruger NJ, von Schaewen A. Curr Opin Plant Biol, The oxidative pentose phosphate pathway: structure and organisation.,, 2003, 6,, 236-246,","journal-title":"Curr Opin Plant Biol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/ijc.22227","volume":"119","author":"Ramos-Montoya A.","year":"2006","unstructured":"Ramos-Montoya A, Lee W-NP, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, No\u00e9 V, Centelles JJ, Cascante M. Int J Cancer, Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer.,, 2006, 119,, 2733-2741,","journal-title":"Int J Cancer"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canlet.2007.01.010","volume":"253","author":"Zhang S.","year":"2007","unstructured":"Zhang S, Yang J-H, Guo C-K, Cai P-C. Cancer Lett, Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells.,, 2007, 253,, 108-114,","journal-title":"Cancer Lett"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00535-013-0895-x","volume":"49","author":"Shimizu T.","year":"2014","unstructured":"Shimizu T, Inoue K, Hachiya H, Shibuya N, Shimoda M, Kubota K. J Gastroenterol, Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas.,, 2014, 49,, 1324-1332,","journal-title":"J Gastroenterol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fonc.2017.00087","volume":"7","author":"Kowalik M.A.","year":"2017","unstructured":"Kowalik MA, Columbano A, Perra A. Front Oncol, Emerging role of the pentose phosphate pathway in hepatocellular carcinoma.,, 2017, 7,, 87-,","journal-title":"Front Oncol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1073\/pnas.54.4.1218","volume":"54","author":"Katzen H.M.","year":"1965","unstructured":"Katzen HM, Schimke RT. Proc Natl Acad Sci USA, Multiple forms of hexokinase in the rat: tissue distribution, age dependency, and properties.,, 1965, 54,, 1218-1225,","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000134593","volume":"77","author":"Sebastian S.","year":"1997","unstructured":"Sebastian S. Cytogenet Genome Res, hoebee, B.; Hande, M.P.; Kenkare, U.W.; Natarajan, A.T. Assignment of hexokinase types 1, 2, 3 (Hk1, 2, 3) and glucokinase (Gck) to rat chromosome band 20q11, 4q34, 17q12 and 14q21 respectively, by in situ hybridization.,, 1997, 77,, 266-267,","journal-title":"Cytogenet Genome Res"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1242\/jeb.00241","volume":"206","author":"Wilson J.E.","year":"2003","unstructured":"Wilson JE. J Exp Biol, Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function.,, 2003, 206,, 2049-2057,","journal-title":"J Exp Biol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0167-4889(97)00150-X","volume":"1401","author":"C\u00e1rdenas M.L.","year":"1998","unstructured":"C\u00e1rdenas ML, Cornish-Bowden A, Ureta T. Biochim Biophys Acta, Evolution and regulatory role of the hexokinases.,, 1998, 1401,, 242-264,","journal-title":"Biochim Biophys Acta"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1101\/gad.889901","volume":"15","author":"Gottlob K.","year":"2001","unstructured":"Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Genes Dev, Inhibition of early apoptotic events by Akt\/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase.,, 2001, 15,, 1406-1418,","journal-title":"Genes Dev"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"43407","DOI":"10.1074\/jbc.M108181200","volume":"276","author":"Mathupala S.P.","year":"2001","unstructured":"Mathupala SP, Rempel A, Pedersen PL. J Biol Chem, Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions.,, 2001, 276,, 43407-43412,","journal-title":"J Biol Chem"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0304-3835(94)90142-2","volume":"82","author":"Shinohara Y.","year":"1994","unstructured":"Shinohara Y, Yamamoto K, Kogure K, Ichihara J, Terada H. Cancer Lett, Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines.,, 1994, 82,, 27-32,","journal-title":"Cancer Lett"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/pro.5560020104","volume":"2","author":"Bork P.","year":"1993","unstructured":"Bork P, Sander C, Valencia A. Protein Sci, Convergent evolution of similar enzymatic function on different protein folds: The hexokinase, ribokinase, and galactokinase families of sugar kinases.,, 1993, 2,, 31-40,","journal-title":"Protein Sci"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BFb0049776","volume":"126","author":"Wilson J.E.","year":"1995","unstructured":"Wilson JE. Rev Physiol Biochem Pharmacol, Hexokinases.,, 1995, 126,, 65-198,","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/0167-4781(94)90225-9","volume":"1219","author":"Rempel A.","year":"1994","unstructured":"Rempel A, Bannasch P, Mayer D. Biochim Biophys Acta, Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages.,, 1994, 1219,, 660-668,","journal-title":"Biochim Biophys Acta"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10863-007-9094-x","volume":"39","author":"Pedersen P.L.","year":"2007","unstructured":"Pedersen PL. J Bioenerg Biomembr, Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers\u2019 most common phenotypes, the \u201cWarburg Effect\u201d, i.e., elevated glycolysis in the presence of oxygen.,, 2007, 39,, 211-222,","journal-title":"J Bioenerg Biomembr"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"13482","DOI":"10.1074\/jbc.M708216200","volume":"283","author":"Abu-Hamad S.","year":"2008","unstructured":"Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. J Biol Chem, Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding.,, 2008, 283,, 13482-13490,","journal-title":"J Biol Chem"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10863-008-9147-9","volume":"40","author":"Shoshan-Barmatz V.","year":"2008","unstructured":"Shoshan-Barmatz V, Keinan N, Zaid H. J Bioenerg Biomembr, Uncovering the role of VDAC in the regulation of cell life and death.,, 2008, 40,, 183-191,","journal-title":"J Bioenerg Biomembr"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.18632\/oncotarget.3800","volume":"6","author":"Dai W.","year":"2015","unstructured":"Dai W, Wang F, Lu J, Xia Y, He L, Chen K, Li J, Li S, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Abudumijiti H, Chen R, Zhang R, Zhou L, Zhou Z, Zhu R, Yang J, Wang C, Zhang H, Zhou Y, Xu L, Guo C. Oncotarget, By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.,, 2015, 6,, 13703-13717,","journal-title":"Oncotarget"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12032-011-9841-z","volume":"29","author":"Gong L.","year":"2012","unstructured":"Gong L, Cui Z, Chen P, Han H, Peng J, Leng X. Med Oncol, Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.,, 2012, 29,, 909-914,","journal-title":"Med Oncol"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10620-014-3364-3","volume":"60","author":"Guzman G.","year":"2015","unstructured":"Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu P-Z, Xie H, Hay N. Dig Dis Sci, Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma.,, 2015, 60,, 420-426,","journal-title":"Dig Dis Sci"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3892\/mmr.2015.3416","volume":"12","author":"Li Y.","year":"2015","unstructured":"Li Y, Lu Z, Liang Z, Ji D, Zhang P, Liu Q, Zheng X, Yao Y. Mol Med Rep, Metastasis-associated in colon cancer-1 is associated with poor prognosis in hepatocellular carcinoma, partly by promoting proliferation through enhanced glucose metabolism.,, 2015, 12,, 426-434,","journal-title":"Mol Med Rep"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/iub.393","volume":"62","author":"Sola-Penna M.","year":"2010","unstructured":"Sola-Penna M, Da Silva D, Coelho WS, Marinho-Carvalho MM, Zancan P. IUBMB Life, Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its implication for the control of the metabolism.,, 2010, 62,, 791-796,","journal-title":"IUBMB Life"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"28479","DOI":"10.1038\/srep28479","volume":"6","author":"Li S.","year":"2016","unstructured":"Li S, Wu L, Feng J, Li J, Liu T, Zhang R, Xu S, Cheng K, Zhou Y, Zhou S, Kong R, Chen K, Wang F, Xia Y, Lu J, Zhou Y, Dai W, Guo C. Sci Rep, In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity.,, 2016, 6,, 28479-,","journal-title":"Sci Rep"},{"key":"ref=118","first-page":"3","volume":"11","author":"Vora S.","year":"1983","unstructured":"Vora S. Isozymes, Isozymes of human phosphofructokinase: biochemical and genetic aspects.,, 1983, 11,, 3-23,","journal-title":"Isozymes"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.critrevonc.2014.05.007","volume":"92","author":"Hasawi N.A.","year":"2014","unstructured":"Hasawi NA, Alkandari MF, Luqmani YA. Crit Rev Oncol Hematol, Phosphofructokinase: A mediator of glycolytic flux in cancer progression.,, 2014, 92,, 312-321,","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"Kroemer G.","year":"2008","unstructured":"Kroemer G, Pouyssegur J. Cancer Cell, Tumor cell metabolism: cancer\u2019s achilles\u2019 heel.,, 2008, 13,, 472-482,","journal-title":"Cancer Cell"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/med.21325","volume":"35","author":"Oliveira P.F.","year":"2015","unstructured":"Oliveira PF, Martins AD, Moreira AC, Cheng CY, Alves MG. Med Res Rev, The warburg effect revisited-lesson from the sertoli cell.,, 2015, 35,, 126-151,","journal-title":"Med Res Rev"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1742-4658.2007.05686.x","volume":"274","author":"Moreno-Sanchez R.","year":"2007","unstructured":"Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernindez A, Saavedra E. FEBS J, Energy metabolism in tumor cells.,, 2007, 274,, 1393-1418,","journal-title":"FEBS J"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1128\/MCB.23.20.7315-7328.2003","volume":"23","author":"Rathmell J.C.","year":"2003","unstructured":"Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Mol Cell Biol, Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.,, 2003, 23,, 7315-7328,","journal-title":"Mol Cell Biol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/jcb.24039","volume":"113","author":"Moreno-S\u00e1nchez R.","year":"2012","unstructured":"Moreno-S\u00e1nchez R, Mar\u00edn-Hern\u00e1ndez A, Gallardo-P\u00e9rez JC, Quezada H, Encalada R, Rodr\u00edguez-Enr\u00edquez S, Saavedra E. J Cell Biochem, Phosphofructokinase type 1 kinetics, isoform expression, and gene polymorphisms in cancer cells.,, 2012, 113,, 1692-1703,","journal-title":"J Cell Biochem"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.biocel.2012.08.013","volume":"44","author":"Vaz C.","year":"2012","unstructured":"Vaz C, Alves M, Marques R, Moreira P, Oliveira P, Maia C, Socorro S. Int J Biochem Cell Biol, Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile.,, 2012, 44,, 2077-2084,","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"e86872","DOI":"10.1371\/journal.pone.0086872","volume":"9","author":"Liu A.M.","year":"2014","unstructured":"Liu AM, Xu Z, Shek FH, Wong K-F, Lee NP, Poon RT, Chen J, Luk JM. PLoS One, miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.,, 2014, 9,, e86872-,","journal-title":"PLoS One"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0014-4827(85)90497-5","volume":"161","author":"Cattaneo A.","year":"1985","unstructured":"Cattaneo A, Biocca S, Corvaja N, Calissano P. Exp Cell Res, Nuclear localization of a lactic dehydrogenase with single-stranded DNA-binding properties.,, 1985, 161,, 130-140,","journal-title":"Exp Cell Res"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bjc.6601205","volume":"89","author":"Koukourakis M.I.","year":"2003","unstructured":"Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL. Br J Cancer, Tumour and angiogenesis research group. lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.,, 2003, 89,, 877-885,","journal-title":"Br J Cancer"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1245\/s10434-008-9955-5","volume":"15","author":"Kolev Y.","year":"2008","unstructured":"Kolev Y, Uetake H, Takagi Y, Sugihara K. Ann Surg Oncol, Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.,, 2008, 15,, 2336-2344,","journal-title":"Ann Surg Oncol"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1200\/JCO.2006.05.9501","volume":"24","author":"Koukourakis M.I.","year":"2006","unstructured":"Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. J Clin Oncol, Tumour angiogenesis research group. lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.,, 2006, 24,, 4301-4308,","journal-title":"J Clin Oncol"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ygyno.2006.05.043","volume":"103","author":"Giatromanolaki A.","year":"2006","unstructured":"Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI. Gynecol Oncol, Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF\/VEGFR2(KDR) pathway and prognosis.,, 2006, 103,, 912-918,","journal-title":"Gynecol Oncol"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2049-3002-1-19","volume":"1","author":"Billiard J.","year":"2013","unstructured":"Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Col\u00f3n M, Dodson CS, Gilbert SA, Greshock J, Jing J, Lu H, McSurdy-Freed JE, Orband-Miller LA, Mills GB, Quinn CJ, Schneck JL, Scott GF, Shaw AN, Waitt GM, Wooster RF, Duffy KJ. Cancer Metab, Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.,, 2013, 1,, 19-,","journal-title":"Cancer Metab"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","volume":"9","author":"Fantin V.R.","year":"2006","unstructured":"Fantin VR, St-Pierre J, Leder P. Cancer Cell, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.,, 2006, 9,, 425-434,","journal-title":"Cancer Cell"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/j.1742-4658.2012.08748.x","volume":"279","author":"Sheng S.L.","year":"2012","unstructured":"Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP, Huang G. FEBS J, Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.,, 2012, 279,, 3898-3910,","journal-title":"FEBS J"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0009-8981(88)90359-2","volume":"173","author":"Kanno T.","year":"1988","unstructured":"Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutake K. Clin Chim Acta, Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy.,, 1988, 173,, 89-98,","journal-title":"Clin Chim Acta"},{"key":"ref=136","first-page":"409","volume":"19","author":"Yang Z.","year":"2015","unstructured":"Yang Z, Ye P, Xu Q, Lu Y, Tang B, Wang Q, Chen S, Chen X. Discov Med, Elevation of serum GGT and LDH levels, together with higher BCLC staging are associated with poor overall survival from hepatocellular carcinoma: a retrospective analysis.,, 2015, 19,, 409-418,","journal-title":"Discov Med"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/oxfordjournals.jbchem.a129852","volume":"71","author":"Imamura K.","year":"1972","unstructured":"Imamura K, Tanaka T. J Biochem, Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies.,, 1972, 71,, 1043-1051,","journal-title":"J Biochem"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.jbchem.a128639","volume":"62","author":"Tanaka T.","year":"1967","unstructured":"Tanaka T, Harano Y, Sue F, Morimura H. J Biochem, Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated from rat tissues.,, 1967, 62,, 71-91,","journal-title":"J Biochem"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semcancer.2005.04.009","volume":"15","author":"Mazurek S.","year":"2005","unstructured":"Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Semin Cancer Biol, Pyruvate kinase type M2 and its role in tumor growth and spreading.,, 2005, 15,, 300-308,","journal-title":"Semin Cancer Biol"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.18632\/oncotarget.2749","volume":"6","author":"Liu W-R.","year":"2015","unstructured":"Liu W-R, Tian M-X, Yang L-X, Lin Y-L, Jin L, Ding Z-B, Shen Y-H, Peng Y-F, Gao D-M, Zhou J. Oncotarget, PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.,, 2015, 6,, 846-861,","journal-title":"Oncotarget"},{"key":"ref=141","first-page":"2538","volume":"6","author":"Chen Z.","year":"2015","unstructured":"Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W, Gao Q, He X. Oncotarget, Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.,, 2015, 6,, 2538-2548,","journal-title":"Oncotarget"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.18632\/oncotarget.3262","volume":"6","author":"Hu W.","year":"2015","unstructured":"Hu W, Lu S-X, Li M, Zhang C, Liu L-L, Fu J, Jin J-T, Luo R-Z, Zhang CZ, Yun J-P. Oncotarget, Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.,, 2015, 6,, 6570-6583,","journal-title":"Oncotarget"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"16615","DOI":"10.1074\/jbc.R114.563148","volume":"289","author":"Patel M.S.","year":"2014","unstructured":"Patel MS, Nemeria NS, Furey W, Jordan F. J Biol Chem, The pyruvate dehydrogenase complexes: structure-based function and regulation.,, 2014, 289,, 16615-16623,","journal-title":"J Biol Chem"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1128\/MCB.00440-07","volume":"27","author":"Kim J.","year":"2007","unstructured":"Kim J, Gao P, Liu Y-C, Semenza GL, Dang CV. Mol Cell Biol, Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.,, 2007, 27,, 7381-7393,","journal-title":"Mol Cell Biol"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjc.2012.559","volume":"108","author":"Shen Y-C.","year":"2013","unstructured":"Shen Y-C, Ou D-L, Hsu C, Lin K-L, Chang C-Y, Lin C-Y, Liu S-H, Cheng A-L. Br J Cancer, Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.,, 2013, 108,, 72-81,","journal-title":"Br J Cancer"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.molcel.2011.10.015","volume":"44","author":"Hitosugi T.","year":"2011","unstructured":"Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J. Mol Cell, Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.,, 2011, 44,, 864-877,","journal-title":"Mol Cell"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"Pelicano H.","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P. Oncogene, Glycolysis inhibition for anticancer treatment.,, 2006, 25,, 4633-4646,","journal-title":"Oncogene"},{"key":"ref=148","first-page":"3561","volume":"26","author":"Zhang X.D.","year":"\u2022\u2022\u2022","unstructured":"Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P. Anticancer Res, Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.,, \u2022\u2022\u2022, 26,, 3561-3566,","journal-title":"Anticancer Res"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0006-2952(02)01456-9","volume":"64","author":"Liu H.","year":"2002","unstructured":"Liu H, Savaraj N, Priebe W, Lampidis TJ. Biochem Pharmacol, Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C).,, 2002, 64,, 1745-1751,","journal-title":"Biochem Pharmacol"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3727\/105221616X693855","volume":"17","author":"Reyes R.","year":"2017","unstructured":"Reyes R, Wani NA, Ghoshal K, Jacob ST, Motiwala T. Gene Expr, Sorafenib and 2-deoxyglucose synergistically inhibit proliferation of both sorafenib-sensitive and -resistant HCC cells by inhibiting ATP production.,, 2017, 17,, 129-140,","journal-title":"Gene Expr"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3892\/ol.2016.5510","volume":"13","author":"Tomizawa M.","year":"2017","unstructured":"Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Oncol Lett, 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.,, 2017, 13,, 800-804,","journal-title":"Oncol Lett"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3892\/mmr.2014.2945","volume":"11","author":"Wang Z.","year":"2015","unstructured":"Wang Z, Zhang L, Zhang D, Sun R, Wang Q, Liu X. Mol Med Rep, Glycolysis inhibitor 2-deoxy-D-glucose suppresses carcinogen-induced rat hepatocarcinogenesis by restricting cancer cell metabolism.,, 2015, 11,, 1917-1924,","journal-title":"Mol Med Rep"},{"key":"ref=153","first-page":"96","volume":"19","author":"Vijayaraghavan R.","year":"2006","unstructured":"Vijayaraghavan R, Kumar D, Dube SN, Singh R, Pandey KS, Bag BC, Kaushik MP, Sekhar K, Dwarakanath BS, Ravindranath T. Biomed Environ Sci, Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser.,, 2006, 19,, 96-103,","journal-title":"Biomed Environ Sci"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"Raez L.E.","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. Cancer Chemother Pharmacol, A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors.,, 2013, 71,, 523-530,","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"Stein M.","year":"2010","unstructured":"Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS. Prostate, Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.,, 2010, 70,, 1388-1394,","journal-title":"Prostate"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10863-012-9412-9","volume":"44","author":"Nakano A.","year":"2012","unstructured":"Nakano A, Miki H, Nakamura S, Harada T, Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M. J Bioenerg Biomembr, Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.,, 2012, 44,, 31-38,","journal-title":"J Bioenerg Biomembr"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0003-9861(90)90273-2","volume":"278","author":"Ko Y.H.","year":"1990","unstructured":"Ko YH, McFadden BA. Arch Biochem Biophys, Alkylation of isocitrate lyase from Escherichia coli by 3-bromopyruvate.,, 1990, 278,, 373-380,","journal-title":"Arch Biochem Biophys"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","volume":"173","author":"Ko Y.H.","year":"2001","unstructured":"Ko YH, Pedersen PL, Geschwind JF. Cancer Lett, Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.,, 2001, 173,, 83-91,","journal-title":"Cancer Lett"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"e0174271","DOI":"10.1371\/journal.pone.0174271","volume":"12","author":"Lee M.","year":"2017","unstructured":"Lee M, Jo A, Lee Kim JB, Chang Y, Nam JY, Cho H, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. PLoS One, 3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.,, 2017, 12,, e0174271-,","journal-title":"PLoS One"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/or.2015.4370","volume":"35","author":"Tomizawa M.","year":"2016","unstructured":"Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Oncol Rep, Suppressive effects of 3-bromopyruvate on the proliferation and the motility of hepatocellular carcinoma cells.,, 2016, 35,, 59-63,","journal-title":"Oncol Rep"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1871520614666140416105309","volume":"14","author":"Gong L.","year":"2014","unstructured":"Gong L, Wei Y, Yu X, Peng J, Leng X. Anticancer Agents Med Chem, 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells\u202f: in vitro and in vivo findings.,, 2014, 14,, 771-776,","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=162","first-page":"923","volume":"30","author":"Ganapathy-Kanniappan S.","year":"2010","unstructured":"Ganapathy-Kanniappan S, Geschwind J-FH, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. Anticancer Res, 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines.,, 2010, 30,, 923-935,","journal-title":"Anticancer Res"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2004.09.047","volume":"324","author":"Ko Y.H.","year":"2004","unstructured":"Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Biochem Biophys Res Commun, Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.,, 2004, 324,, 269-275,","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=164","first-page":"3909","volume":"62","author":"Geschwind J-F.H.","year":"2002","unstructured":"Geschwind J-FH, Ko YH, Torbenson MS, Magee C, Pedersen PL. Cancer Res, Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.,, 2002, 62,, 3909-3913,","journal-title":"Cancer Res"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10863-012-9417-4","volume":"44","author":"Ko Y.H.","year":"2012","unstructured":"Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. J Bioenerg Biomembr, A translational study \u201ccase-report\u201d on the small molecule \u201cenergy blocker\u201d 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.,, 2012, 44,, 163-170,","journal-title":"J Bioenerg Biomembr"},{"key":"ref=166","first-page":"356","volume":"33","author":"El Sayed S.M.","year":"2014","unstructured":"El Sayed SM, Mohamed WG, Seddik M-AH, Ahmed A-SA, Mahmoud AG, Amer WH, Helmy Nabo MM, Hamed AR, Ahmed NS, Abd-Allah AA-R. Chin J Cancer, Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.,, 2014, 33,, 356-364,","journal-title":"Chin J Cancer"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","volume":"11","author":"Bonnet S.","year":"2007","unstructured":"Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED. Cancer Cell, A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.,, 2007, 11,, 37-51,","journal-title":"Cancer Cell"},{"key":"ref=168","first-page":"617","volume":"1846","author":"Kankotia S.","year":"2014","unstructured":"Kankotia S, Stacpoole PW. Biochim Biophys Acta, Dichloroacetate and cancer: new home for an orphan drug?,, 2014, 1846,, 617-629,","journal-title":"Biochim Biophys Acta"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp200571k","volume":"9","author":"Xue X.","year":"2012","unstructured":"Xue X, You S, Zhang Q, Wu Y, Zou GZ, Wang PC, Zhao YL, Xu Y, Jia L, Zhang X, Liang XJ. Mol Pharm, Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.,, 2012, 9,, 634-644,","journal-title":"Mol Pharm"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"e92962","DOI":"10.1371\/journal.pone.0092962","volume":"9","author":"Dai Y.","year":"2014","unstructured":"Dai Y, Xiong X, Huang G, Liu J, Sheng S, Wang H, Qin W. PLoS One, Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels.,, 2014, 9,, e92962-,","journal-title":"PLoS One"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11010-010-0397-6","volume":"340","author":"Xiao L.","year":"2010","unstructured":"Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y. Mol Cell Biochem, Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7\/IL-24.,, 2010, 340,, 31-40,","journal-title":"Mol Cell Biochem"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1289\/ehp.1002554","volume":"119","author":"Stacpoole P.W.","year":"2011","unstructured":"Stacpoole PW. Environ Health Perspect, The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?,, 2011, 119,, 155-158,","journal-title":"Environ Health Perspect"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/01.wnl.0000196641.05913.27","volume":"66","author":"Kaufmann P.","year":"2006","unstructured":"Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS, Hong X, Gooch CL, Mao X, Pascual JM. Neurology, Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial.,, 2006, 66,, 324-330,","journal-title":"Neurology"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"Deininger M.W.","year":"1997","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV. Blood, The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.,, 1997, 90,, 3691-3698,","journal-title":"Blood"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","volume":"10","author":"Gottschalk S.","year":"2004","unstructured":"Gottschalk S, Anderson N, Hainz C, Leukemia H, Cells BP, Eckhardt SG, Serkova NJ. Clin Cancer Res, Imatinib (STI571) -mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells imatinib (STI571) -Mediated Changes in Glucose Metabolism.,, 2004, 10,, 6661-6668,","journal-title":"Clin Cancer Res"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-800173-8.00006-4","volume":"39","author":"Al-Hadiya B.M.H.","year":"2014","unstructured":"Al-Hadiya BMH, Bakheit AHH, Abd-Elgalil AA. Profiles Drug Subst Excip Relat Methodol, Chapter Six - Imatinib Mesylate.,, 2014, 39,, 265-297,","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.phrs.2010.12.005","volume":"63","author":"Fiume L.","year":"2011","unstructured":"Fiume L, Vettraino M, Manerba M, Di Stefano G. Pharmacol Res, Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.,, 2011, 63,, 328-334,","journal-title":"Pharmacol Res"},{"key":"ref=178","first-page":"29","volume":"10","author":"Keshavarz-Pakseresht B.","year":"2017","unstructured":"Keshavarz-Pakseresht B, Shandiz SAS, Baghbani-Arani F. Gastroenterol Hepatol, Imatinib induces up-regulation of NM23, a metastasis suppressor gene, in human Hepatocarcinoma (HepG2) Cell Line.,, 2017, 10,, 29-33,","journal-title":"Gastroenterol Hepatol"},{"key":"ref=179","author":"Knight B.","year":"2008","unstructured":"Knight B, Tirnitz-Parker JEE, Olynyk JK. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice., , , 2008","journal-title":"C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1432-0436.2007.00235.x","volume":"75","author":"Campbell J.S.","year":"2007","unstructured":"Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Differentiation, Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.,, 2007, 75,, 843-852,","journal-title":"Differentiation"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.canlet.2007.10.041","volume":"260","author":"Treiber G.","year":"2008","unstructured":"Treiber G, Wex T, Schleyer E, Troeger U, Hosius C, Malfertheiner P. Cancer Lett, Imatinib for hepatocellular cancer--focus on pharmacokinetic\/pharmacodynamic modelling and liver function.,, 2008, 260,, 146-154,","journal-title":"Cancer Lett"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00001813-200404000-00014","volume":"15","author":"Ramadori G.","year":"2004","unstructured":"Ramadori G, F\u00fczesi L, Grabbe E, Pieler T, Armbrust T. Anticancer Drugs, Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.,, 2004, 15,, 405-409,","journal-title":"Anticancer Drugs"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/COC.0b013e3181131db9","volume":"31","author":"Lin A.Y.","year":"2008","unstructured":"Lin AY, Fisher GA, So S, Tang C, Levitt L, Phase II. Am J Clin Oncol, Study of Imatinib in Unresectable Hepatocellular Carcinoma.,, 2008, 31,, 84-88,","journal-title":"Am J Clin Oncol"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000089990","volume":"69","author":"Eckel F.","year":"2005","unstructured":"Eckel F, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, Schleyer E, Schulte-Frohlinde E, Schmid RM, Lersch C. Oncology, Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.,, 2005, 69,, 363-371,","journal-title":"Oncology"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.mce.2012.10.024","volume":"365","author":"Huang J.","year":"2013","unstructured":"Huang J, Huang K, Lan T, Xie X, Shen X, Liu P, Huang H. Mol Cell Endocrinol, Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway.,, 2013, 365,, 231-240,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=186","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ptr.5201","volume":"28","author":"Neerati P.","year":"2014","unstructured":"Neerati P, Devde R, Gangi AK. Phytother Res, Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus.,, 2014, 28,, 1796-1800,","journal-title":"Phytother Res"},{"key":"ref=187","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jnutbio.2012.04.013","volume":"24","author":"Soetikno V.","year":"2013","unstructured":"Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K, Kawachi H, Watanabe K. J Nutr Biochem, Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats.,, 2013, 24,, 796-802,","journal-title":"J Nutr Biochem"},{"key":"ref=188","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/etm.2015.2749","volume":"10","author":"Perrone D.","year":"2015","unstructured":"Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo LDE, Lillo A, Laino L, Lo Muzio L. Exp Ther Med, Biological and therapeutic activities, and anticancer properties of curcumin.,, 2015, 10,, 1615-1623,","journal-title":"Exp Ther Med"},{"key":"ref=189","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2174\/1568026615666150619142519","volume":"15","author":"Nabavi S.F.","year":"2015","unstructured":"Nabavi SF, Thiagarajan R, Rastrelli L, Daglia M, Sobarzo-S\u00e1nchez E, Alinezhad H, Nabavi SM. Curr Top Med Chem, Curcumin: a natural product for diabetes and its complications.,, 2015, 15,, 2445-2455,","journal-title":"Curr Top Med Chem"},{"key":"ref=190","first-page":"645","volume":"\u2022\u2022\u2022","author":"Vallianou N.G.","year":"2015","unstructured":"Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Anticancer Res, Potential anticancer properties and mechanisms of action of curcumin.,, 2015, \u2022\u2022\u2022,, 645-651,","journal-title":"Anticancer Res"},{"key":"ref=191","author":"Gunnink L.K.","year":"2016","unstructured":"Gunnink LK, Alabi OD, Kuiper BD, Gunnink SM, Schuiteman SJ, Strohbehn LE, Hamilton KE, Wrobel KE, Louters LL. Biochimie, Curcumin directly inhibits the transport activity of GLUT1.,, 2016, \u2022\u2022\u2022,, 645-,","journal-title":"Biochimie"},{"key":"ref=192","doi-asserted-by":"crossref","first-page":"108498","DOI":"10.18632\/oncotarget.22590","volume":"8","author":"Cao M.T.","year":"2017","unstructured":"Cao MT, Liu HF, Liu ZG, Xiao P, Chen JJ, Tan Y, Jiang XX, Jiang ZC, Qiu Y, Huang HJ, Zhang QG. Oncotarget, Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-\u03b21-induced epithelial-mesenchymal transitions in hepatoma cells.,, 2017, 8,, 108498-108508,","journal-title":"Oncotarget"},{"key":"ref=193","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.freeradbiomed.2007.06.006","volume":"43","author":"Cao J.","year":"2007","unstructured":"Cao J, Liu Y, Jia L, Zhou H-M, Kong Y, Yang G, Jiang L-P, Li Q-J, Zhong L-F. Free Radic Biol Med, Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells.,, 2007, 43,, 968-975,","journal-title":"Free Radic Biol Med"},{"key":"ref=194","first-page":"1557","volume":"15","author":"Bae M-K.","year":"2006","unstructured":"Bae M-K, Kim S-H, Jeong J-W, Lee YM, Kim H-S, Kim S-R, Yun I, Bae S-K, Kim K-W. Oncol Rep, Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1.,, 2006, 15,, 1557-1562,","journal-title":"Oncol Rep"},{"key":"ref=195","first-page":"1435","volume":"23","author":"Xiao J.","year":"2010","unstructured":"Xiao J, Chu Y, Hu K, Wan J, Huang Y, Jiang C, Liang G, Li X. Oncol Rep, Synthesis and biological analysis of a new curcumin analogue for enhanced anti-tumor activity in HepG 2 cells.,, 2010, 23,, 1435-1441,","journal-title":"Oncol Rep"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.febslet.2008.06.048","volume":"582","author":"Wang W-Z.","year":"2008","unstructured":"Wang W-Z, Cheng J, Luo J, Zhuang S-M. FEBS Lett, Abrogation of G2\/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis.,, 2008, 582,, 2689-2695,","journal-title":"FEBS Lett"},{"key":"ref=197","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1124\/mol.106.025817","volume":"70","author":"Choi H.","year":"2006","unstructured":"Choi H, Chun Y-S, Kim S-W, Kim M-S, Park J-W. Mol Pharmacol, Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.,, 2006, 70,, 1664-1671,","journal-title":"Mol Pharmacol"},{"key":"ref=198","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3892\/ol.2014.2694","volume":"9","author":"Gao J-Z.","year":"2015","unstructured":"Gao J-Z. Oncol Lett, DU, J.-L.; Wang, Y.-L.; Li, J.; Wei, L.-X.; Guo, M.-Z. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma.,, 2015, 9,, 295-299,","journal-title":"Oncol Lett"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s13277-014-2767-2","volume":"36","author":"Ahmed H.H.","year":"2015","unstructured":"Ahmed HH, Shousha WG, Shalby AB, El-Mezayen HA, Ismaiel NN, Mahmoud NS. Tumour Biol, Curcumin: a unique antioxidant offers a multimechanistic approach for management of hepatocellular carcinoma in rat model.,, 2015, 36,, 1667-1678,","journal-title":"Tumour Biol"},{"key":"ref=200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3892\/etm.2016.3952","volume":"13","author":"El-Houseini M.E.","year":"2017","unstructured":"El-Houseini ME, El-Agoza IA, Sakr MM, El-Malky GM. Exp Ther Med, Novel protective role of curcumin and taurine combination against experimental hepatocarcinogenesis.,, 2017, 13,, 29-36,","journal-title":"Exp Ther Med"},{"key":"ref=201","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mc.22718","volume":"57","author":"Zhang H-H.","year":"2018","unstructured":"Zhang H-H, Zhang Y, Cheng Y-N, Gong F-L, Cao Z-Q, Yu L-G, Guo X-L. Mol Carcinog, Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.,, 2018, 57,, 44-56,","journal-title":"Mol Carcinog"},{"key":"ref=202","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1756-9966-28-80","volume":"28","author":"Seufi A.M.","year":"2009","unstructured":"Seufi AM, Ibrahim SS, Elmaghraby TK, Hafez EE. J Exp Clin Cancer Res, Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant\/antioxidant activity: molecular and histological evidences.,, 2009, 28,, 80-,","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=203","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/ptr.5488","volume":"29","author":"Lee S.H.","year":"2015","unstructured":"Lee SH, Yumnam S, Hong GE, Raha S, Venkatarame Gowda Saralamma V, Lee HJ, Heo JD, Lee SJ, Lee WS, Kim EH, Park HS. Phytother Res, Flavonoids of Korean Citrus aurantium L. induce apoptosis via intrinsic pathway in human hepatoblastoma HepG2 cells.,, 2015, 29,, 1940-1949,","journal-title":"Phytother Res"},{"key":"ref=204","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1248\/bpb.31.1403","volume":"31","author":"Nomura M.","year":"2008","unstructured":"Nomura M, Takahashi T, Nagata N, Tsutsumi K, Kobayashi S, Akiba T, Yokogawa K, Moritani S, Miyamoto K. Biol Pharm Bull, Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2\/PA6 adipose cells.,, 2008, 31,, 1403-1409,","journal-title":"Biol Pharm Bull"},{"key":"ref=205","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1006\/bbrc.1999.0890","volume":"260","author":"Park J.B.","year":"1999","unstructured":"Park JB. Biochem Biophys Res Commun, Flavonoids are potential inhibitors of glucose uptake in U937 cells.,, 1999, 260,, 568-574,","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cbi.2003.06.001","volume":"146","author":"Martin H.J.","year":"2003","unstructured":"Martin HJ, Kornmann F, Fuhrmann GF. Chem Biol Interact, The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes.,, 2003, 146,, 225-235,","journal-title":"Chem Biol Interact"},{"key":"ref=207","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/01635581.2016.1145245","volume":"68","author":"Brito A.F.","year":"2016","unstructured":"Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gon\u00e7alves AC, Sarmento-Ribeiro AB, Tralh\u00e3o JG, Botelho MF. Nutr Cancer, New Approach for treatment of primary liver tumors: the role of quercetin.,, 2016, 68,, 250-266,","journal-title":"Nutr Cancer"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s13277-015-4501-0","volume":"37","author":"Dai W.","year":"2016","unstructured":"Dai W, Gao Q, Qiu J, Yuan J, Wu G, Shen G. Tumour Biol, Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.,, 2016, 37,, 6307-6313,","journal-title":"Tumour Biol"},{"key":"ref=209","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3892\/ijo.2017.3886","volume":"50","author":"Ren K-W.","year":"2017","unstructured":"Ren K-W, Li Y-H, Wu G, Ren J-Z, Lu H-B, Li Z-M, Han X-W. Int J Oncol, Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells.,, 2017, 50,, 1299-1311,","journal-title":"Int J Oncol"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2174\/0929867322666150812145435","volume":"22","author":"Brito A.F.","year":"2015","unstructured":"Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralh\u00e3o JG, Botelho MF. Curr Med Chem, Quercetin in cancer treatment, alone or in combination with conventional therapeutics?,, 2015, 22,, 3025-3039,","journal-title":"Curr Med Chem"},{"key":"ref=211","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CEJ.0b013e32834a7e2b","volume":"21","author":"Ghosh A.","year":"2012","unstructured":"Ghosh A, Ghosh D, Sarkar S, Mandal AK, Thakur Choudhury S, Das N. Eur J Cancer Prev, Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats.,, 2012, 21,, 32-41,","journal-title":"Eur J Cancer Prev"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-05-2365","volume":"12","author":"Yuan Z.P.","year":"2006","unstructured":"Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, Wang GQ, Yao WX, Zhao QM, Ye B. Clin Cancer Res, Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.,, 2006, 12,, 3193-3199,","journal-title":"Clin Cancer Res"},{"key":"ref=213","first-page":"497","volume":"66","author":"Floridi A.","year":"1981","unstructured":"Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. J Natl Cancer Inst, Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.,, 1981, 66,, 497-499,","journal-title":"J Natl Cancer Inst"},{"key":"ref=214","first-page":"4661","volume":"41","author":"Floridi A.","year":"1981","unstructured":"Floridi A, Paggi MG, D\u2019Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A. Cancer Res, Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.,, 1981, 41,, 4661-4666,","journal-title":"Cancer Res"},{"key":"ref=215","first-page":"2814","volume":"55","author":"Ben-Horin H.","year":"1995","unstructured":"Ben-Horin H, Tassini M, Vivi A, Navon G, Kaplan O. Cancer Res, Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies.,, 1995, 55,, 2814-2821,","journal-title":"Cancer Res"},{"key":"ref=216","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1005819604858","volume":"36","author":"Ben-Yoseph O.","year":"1998","unstructured":"Ben-Yoseph O, Lyons JC, Song CW, Ross BD. J Neurooncol, Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.,, 1998, 36,, 149-157,","journal-title":"J Neurooncol"},{"key":"ref=217","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood.V97.12.3931","volume":"97","author":"Yuan Z.P.","year":"2001","unstructured":"Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, Wang GQ, Yao WX, Zhao QM, Ye B. Blood, Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.,, 2001, 97,, 3931-3940,","journal-title":"Blood"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q","volume":"82","author":"Biroccio A.","year":"1999","unstructured":"Biroccio A, Del Bufalo D, Fanciulli M, Bruno T, Zupi G, Floridi A. Int J Cancer, bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cells.,, 1999, 82,, 125-130,","journal-title":"Int J Cancer"},{"key":"ref=219","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<377::AID-IJC20>3.0.CO;2-2","volume":"78","author":"Orlandi L.","year":"1998","unstructured":"Orlandi L, Zaffaroni N, Bearzatto A, Villa R, De Marco C, Silvestrini R. Int J Cancer, Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.,, 1998, 78,, 377-384,","journal-title":"Int J Cancer"},{"key":"ref=220","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1038\/sj.onc.1204953","volume":"20","author":"Belzacq A-S.","year":"2001","unstructured":"Belzacq A-S, El Hamel C, Vieira HLA, Cohen I, Haouzi D, M\u00e9tivier D, Marchetti P, Brenner C, Kroemer G. Oncogene, Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437.,, 2001, 20,, 7579-7587,","journal-title":"Oncogene"},{"key":"ref=221","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.onc.1202625","volume":"18","author":"Ravagnan L.","year":"1999","unstructured":"Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z. Oncogene, ,, 1999, 18,, 2537-2546,","journal-title":"Oncogene"},{"key":"ref=222","doi-asserted-by":"crossref","first-page":"690492","DOI":"10.1155\/2015\/690492","volume":"2015","author":"Cervantes-Madrid D.","year":"2015","unstructured":"Cervantes-Madrid D, Romero Y, Due\u00f1as-Gonz\u00e1lez A. BioMed Res Int, Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.,, 2015, 2015,, 690492-,","journal-title":"BioMed Res Int"},{"key":"ref=223","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/onc.2008.114","volume":"27","author":"Galluzzi L.","year":"2008","unstructured":"Galluzzi L, Kepp O, Tajeddine N, Kroemer G. Oncogene, Disruption of the hexokinase-VDAC complex for tumor therapy.,, 2008, 27,, 4633-4635,","journal-title":"Oncogene"},{"key":"ref=224","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/onc.2008.108","volume":"27","author":"Goldin N.","year":"2008","unstructured":"Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, Bronner V, Notcovich A, Shoshan-Barmatz V, Flescher E. Oncogene, Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.,, 2008, 27,, 4636-4643,","journal-title":"Oncogene"},{"key":"ref=225","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1179\/joc.2003.15.5.480","volume":"15","author":"Ricotti L.","year":"2003","unstructured":"Ricotti L, Tesei A, De Paola F, Milandri C, Amadori D, Frassineti GL, Ulivi P, Zoli W. J Chemother, Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells.,, 2003, 15,, 480-487,","journal-title":"J Chemother"},{"key":"ref=226","first-page":"151","volume":"1866","author":"Nath K.","year":"2016","unstructured":"Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP, Blair IA. Biochim Biophys Acta, Mechanism of antineoplastic activity of lonidamine.,, 2016, 1866,, 151-162,","journal-title":"Biochim Biophys Acta"},{"key":"ref=227","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","volume":"473","author":"Nancolas B.","year":"2016","unstructured":"Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, Blair IA, Glickson JD, Halestrap AP. Biochem J, The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.,, 2016, 473,, 929-936,","journal-title":"Biochem J"},{"key":"ref=228","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000317519","volume":"86","author":"Fiume L.","year":"2010","unstructured":"Fiume L, Manerba M, Vettraino M, Di Stefano G. Pharmacology, Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.,, 2010, 86,, 157-162,","journal-title":"Pharmacology"},{"key":"ref=229","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-5793(99)00924-2","volume":"456","author":"Ra\u00efs B.","year":"1999","unstructured":"Ra\u00efs B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Paul Lee W-N, Boros LG, Cascante M. FEBS Lett, Oxythiamine and dehydroepiandrosterone induce a G phase cycle arrest in Ehrlich\u2019s tumor cells through inhibition of the pentose cycle.,, 1999, 456,, 113-118,","journal-title":"FEBS Lett"},{"key":"ref=230","first-page":"4242","volume":"57","author":"Boros L.G.","year":"1997","unstructured":"Boros LG, Puigjaner J, Cascante M, Lee WNP, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ. Cancer Res, Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation.,, 1997, 57,, 4242-4248,","journal-title":"Cancer Res"},{"key":"ref=231","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1046\/j.1432-1327.2001.02329.x","volume":"268","author":"Com\u00edn-Anduix B.","year":"2001","unstructured":"Com\u00edn-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WN, Boros LG, Cascante M. Eur J Biochem, The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study.,, 2001, 268,, 4177-4182,","journal-title":"Eur J Biochem"},{"key":"ref=232","doi-asserted-by":"crossref","first-page":"E725","DOI":"10.1073\/pnas.1508779113","volume":"113","author":"Xu I.M.J.","year":"2016","unstructured":"Xu IMJ, Lai RKH, Lin SH, Tse APW, Chiu DKC, Koh HY, Law CT, Wong CM, Cai Z, Wong CCL, Ng IOL. Proc Natl Acad Sci USA, Transketolase counteracts oxidative stress to drive cancer development.,, 2016, 113,, E725-E734,","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=233","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2162-3619-2-18","volume":"2","author":"Wang J.","year":"2013","unstructured":"Wang J, Zhang X, Ma D, Lee WN, Xiao J, Zhao Y, Go VL, Wang Q, Yen Y, Recker R, Xiao GG. Exp Hematol Oncol, Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells.,, 2013, 2,, 18-,","journal-title":"Exp Hematol Oncol"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/161698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T11:59:58Z","timestamp":1720267198000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/161698\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":234,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009618666180430144441","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}